Neutrophil degranulation involves a number of well-orchestrated structural and biochemical events. We have investigated the mechanism of intracellular signalling involved in neutrophil degranulation that was mediated by the high affinity leukotriene (LT)B[subscript 4] receptor, BLT1. The model systems used were consisted of Peripheral blood neutrophils as well as promyeloid PLB-985 cells, stably transfected with human BLT1 cDNA (PLB-BLT) or a substitution mutant (2L(304-305)/A) of the distal dileucine motif in helix VIII of BLT1, and differentiated into a neutrophil-like phenotype. The degranulation of these cells was measured in the presence and absence of factors that would affect the signaling pathway. The results show that Degranulation responses to LTB[subscript 4] were similar for differentiated PLB-BLT1 and neutrophils. However, the degranulation response of cells bearing the dileucine mutation in helix VIII of BLT1 was significantly reduced in response to LTB[subscript 4]. Pretreatment of differentiated PLB-BLT1 cells and neutrophils with Y-27632, a pharmacological inhibitor of p160-ROCK, the down-stream effector of the small GTPase RhoA, abrogated their degranulation in response to LTB[subscript 4]. The degranulation defect observed with the dileucine mutation was corrected by transient transfection of the cells bearing the mutation with a constitutively active form of RhoA. Taken together, our results suggest an essential role for the distal dileucine motif in helix VIII of BLT1 involving RhoA which allows normal neutrophil degranulation in response to LTB[subscript 4].

Zahlreiche pathogene „missense“-Mutation, die verhindern, dass Proteine korrekt gefaltet werden, befinden sich in geordneten Regionen von Proteinen. Andere krankheitsrelevante Mutationen befinden sich in ungeordneten Regionen und beeinflussen somit nur begrenzt die Funktionalität, zum Beispiel durch Veränderungen kurzer linearer Sequenzmotive, die Protein-Protein Interaktionen vermitteln. In dieser Arbeit wird ein peptidbasierter Interaktionsscreen präsentiert mit dem sich Veränderungen im Interaktom identifizieren lassen. Synthetische Peptide von wild-typ und zugehörigen mutierten Proteinregionen ermöglichen die gleichzeitige Untersuchung von mehr als hundert Mutationen mittels Massenspektrometrie. Mehr als ein Drittel aller getesteten Mutationen hatten veränderte Interaktionen zur Folge. Darunter befanden sich auch drei Prolin zu Leucin Mutationen in zytosolischen Regionen von Transmembranproteinen, die zusammen mit dem benachbarten Leucin einem Dileucinmotiv ergeben und dadurch verstärkt mit Clathrin interagieren. Dieses Motiv wurde bereits mit Clathrin-vermittelter Endozytose in Verbindung gebracht. Die hinzugewonnene Endozytose könnte Krankheitsmechanismen erklären, da die Mislokalisation der betroffenen Transmembranproteine zum effektiven Verlust derer Funktion führen würde. Diese Hypothese wurde hier von verschiedenen in vitro und in vivo Experimenten bezüglich der P485L Mutation im Glukose Transporter-1 (GLUT1), die das GLUT1-Defizit-Syndrom hervorruft, bestätigt. Weitere Evidenz wurde außerdem für die Funktionalität anderer mutationsbedingter Dileucinmotive gewonnen. Die systematische Analyse von pathogenen Mutationen hat gezeigt, dass Dileucinmotive signifikant und spezifisch in ungeordneten zytosolischen Regionen von Transmembranproteinen überrepräsentiert sind. Dieser Peptidescreen macht das Potenzial unvoreingenommener Analysen zur Aufklärung von Krankheitsmechanismen deutlich, die von Veränderungen in Protein-Protein Interaktionen hervorgerufen werden. / Many disease-associated missense mutations prevent proteins from folding correctly and lead to loss-of-function. These mutations are often found in ordered regions of proteins. Another class of disease-related missense mutations can be found in disordered regions. These are thought to impair only specific parts of a protein’s functions. Those mutations could modify short linear motifs that mediate protein-protein interactions. Here, we designed a peptide-based interaction screen to identify interactions that are affected by mutations in disordered regions. We used synthetic peptides corresponding to the wild type and mutated protein regions spotted on cellulose membrane to pull-down interaction partners. This setup allows for the screening of more than hundred mutations at a time via mass spectrometry. Here, we focused on mutations implicated in neurological diseases. More than one-third of tested variant pairs show differential interactions. Three disease-related proline to leucine mutations in cytosolic tails of transmembrane proteins lead to gain of a dileucine sequence. Several dileucine-containing peptide motifs are involved in clathrin-mediated endocytosis (CME). Also in the presented screen, the newly created motifs mediate interaction with the CME machinery. This could explain the disease mechanisms since mislocalization of the affected transmembrane proteins would lead to their loss of function. This hypothesis has been corroborated for glucose transporter-1 (GLUT1) P485L, causing GLUT1 deficiency syndrome. We were able to provide functional evidence also for additional gained dileucine motifs. A systematic analysis of pathogenic mutations revealed dileucine motifs to be overrepresented in structurally disordered cytosolic regions of transmembrane proteins. The data gained with the peptide screen highlights the power of differential interactome mapping as a generic approach to unravel disease mechanisms caused by changes in protein-protein interactions.